Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trialAditya H. Gaur, R. Kiplin Guy, Kristen Branum et al.|The Lancet Infectious Diseases|2020Cited by 77
Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trialJoshua Wolf, Patricia M. Flynn, Tom Connell et al.|The Lancet Infectious Diseases|2018Cited by 65
Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug developmentAditya H. Gaur, R. Kiplin Guy, John C. Panetta et al.|EBioMedicine|2022Cited by 17
Ethanol Lock Treatment and Secondary Prophylaxis for Central Line-Associated Bloodstream Infection in Pediatric Hematology and Oncology: A Randomized, Double-Blind, Placebo-Controlled, Intervention TrialJoshua Wolf, Patricia M. Flynn, Tom Connell et al.|Open Forum Infectious Diseases|2017Cited by 1